Ackman: Allergan misled investors to sink Valeant's shares; NICE recommends Glivec in GIST; Ranbaxy settles Texas case;

@FiercePharma: Tops in FierceVaccines Thurs: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. Story | Follow @FiercePharma

@EricPFierce: I suspect Laura Schumacher spent late nights as AbbVie board decided whether to walk away from Shire deal. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Subscribe here to get it weekly. Subscribe | Follow @CarlyHFierce

> Valeant ($VRX) takeover partner Bill Ackman says his lawyers have documents that show Allergan ($AGN) misled investors to fend off the Canadian pharma's hostile bid. More

> The U.K.'s cost-effectiveness gatekeeper has recommended Novartis' ($NVS) Glivec for up to three years in patients who have had a gastro-intestinal stromal tumor and are at a high risk of recurrence. More

> Ranbaxy Laboratories will pay nearly $40 million to settle a case in Texas saying that it had overpriced drugs to the state Medicaid program. Story

> India's Cadila is recalling 5,400 bottles of its version of the anti-hypertension drug Atenolo because they do not meet specifications. Report

> The government in Egypt has selected 5 drugmakers there to produce generic versions of hep C drug Sovaldi. Story

> Some public interest groups are concerned that patent protections being written into a new Pacific Rim trade pact will delay lower cost generic drugs sales in some poor countries. Story

Medical Device News

@FierceMedDev: Medical device venture deals pull in more money per deal. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Stryker scores with Q3 earnings, beating the Street's expectations and posting $2.39B in revenue. Article | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver #cancer-killing payloads. News | Follow @MichaelGFierce

> Former GE Healthcare head John Dineen joins private equity group. More

> Stryker to repatriate $2B, ready for acquisitions in 2H15. Story

> Boston Scientific wins CE mark for MRI-friendly pacemaker products. News

Biotech News

@FierceBiotech: Astellas backs out of a $760M Alzheimer's deal with CoMentis. Item | Follow @FierceBiotech

@JohnCFierce: This low-T field is definitely starting to look like the slum area of R&D. | Follow @JohnCFierce

@DamianFierce: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Story | Follow @DamianFierce

@EmilyMFierce: The long and ugly tradition of treating Africa as a dirty, diseased place. More | Follow @EmilyMFierce

> Amgen sues to block Sanofi and Regeneron at the PCSK9 goal line. Article

> Repros plummets as the FDA deals a blow to its low-T hopes. Story

> Adaptimmune's novel cancer treatment posts promising early results. More

And Finally... For the third year in a row, Regeneron ($REGN) has topped of Science magazine's top 20 employers survey, followed by Novo Nordisk ($NVO) and Roche's ($RHHBY) Genentech unit. More